0001104659-22-104796.txt : 20220930 0001104659-22-104796.hdr.sgml : 20220930 20220930214913 ACCESSION NUMBER: 0001104659-22-104796 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220928 FILED AS OF DATE: 20220930 DATE AS OF CHANGE: 20220930 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Salain Daniel CENTRAL INDEX KEY: 0001824804 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31918 FILM NUMBER: 221285730 MAIL ADDRESS: STREET 1: C/O GRAYBUG VISION, INC. STREET 2: 275 SHORELINE DRIVE, SUITE 450 CITY: REDWOOD CITY STATE: CA ZIP: 94065 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IDERA PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000861838 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043072298 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 505 EAGLEVIEW BOULEVARD STREET 2: SUITE 212 CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 4843481600 MAIL ADDRESS: STREET 1: 505 EAGLEVIEW BOULEVARD STREET 2: SUITE 212 CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: HYBRIDON INC DATE OF NAME CHANGE: 19951211 4 1 tm2227191-8_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-09-28 0 0000861838 IDERA PHARMACEUTICALS, INC. IDRA 0001824804 Salain Daniel C/O IDERA PHARMACEUTICALS, INC. 505 EAGLEVIEW BLVD. EXTON PA 19341 0 1 0 0 Chief Operating Officer Common Stock, par value $0.001 2022-09-28 4 A 0 2171214 A 2171214 D Series Z Convertible Preferred Stock 2022-09-28 4 A 0 22810 A Common Stock 22810000 22810 D Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. ("Idera") and Aceragen, Inc. ("Aceragen"), dated September 28, 2022, Aceragen merged with and became a wholly-owned subsidiary of Idera (the "Merger"). Pursuant to the Merger, each issued and outstanding share of Aceragen common stock was converted into 2.6332 shares of common stock of Idera, par value $0.001 per share ("Common Stock") and 27.0005 shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 ("Series Z Preferred Stock"). Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is convertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations. /s/ John J. Kirby, Attorney-in-Fact for Daniel Salain 2022-09-30